Here's Why Pfizer Stock Is Still a Buy

Pfizer (NYSE: PFE) got a huge boost during the coronavirus pandemic thanks to its COVID-19 vaccine. Since that point, however, investors have soured on the stock, which has lost more than half its value since its 2021 high-water mark. There are very real concerns to consider with the business, but investor sentiment may have swung too far to the negative here.Pfizer is one of the world's largest pharmaceutical companies, with a long history of innovation. This is an important fact to keep in mind as you look at the stock. The drug industry is capital-intensive due to the heavy research and development spending required. Adding to costs is the regulatory burden drugmakers face, since new drugs must prove both effective and safe before they are allowed to be sold.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool